Distinct high resolution genome profiles of early onset and late onset colorectal cancer integrated with gene expression data identify candidate susceptibility loci.Prediction of overall survival in stage II and III colon cancer beyond TNM system: a retrospective, pooled biomarker study.Prognostic Significance of β-Catenin, E-Cadherin, and SOX9 in Colorectal Cancer: Results from a Large Population-Representative Series.Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset.Phospholipase C isozymes are deregulated in colorectal cancer--insights gained from gene set enrichment analysis of the transcriptome.Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival.B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcomeMiR-9, -31, and -182 deregulation promote proliferation and tumor cell survival in colon cancer.The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancersHigh frequency of fusion transcripts involving TCF7L2 in colorectal cancer: novel fusion partner and splice variants.Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas.SPG20, a novel biomarker for early detection of colorectal cancer, encodes a regulator of cytokinesis.A tissue-based comparative effectiveness analysis of biomarkers for early detection of colorectal tumors.Microsatellite instability has a positive prognostic impact on stage II colorectal cancer after complete resection: results from a large, consecutive Norwegian series.Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy.Common fusion transcripts identified in colorectal cancer cell lines by high-throughput RNA sequencing.Preoperative staging and treatment options in T1 rectal adenocarcinoma.Prognostic impact of genomic instability in colorectal cancer.Portrait of the PI3K/AKT pathway in colorectal cancer.Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study.Regulator of Chromosome Condensation 2 Identifies High-Risk Patients within Both Major Phenotypes of Colorectal Cancer.Anticipating the clinical use of prognostic gene expression-based tests for colon cancer stage II and III: is Godot finally arriving?Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome.UVRAG mutations associated with microsatellite unstable colon cancer do not affect autophagy.National Early Rectal Cancer Treatment Revisited.Lymph node micrometastases and isolated tumor cells influence survival in stage I and II colon cancer.Nationwide improvement of rectal cancer treatment outcomes in Norway, 1993-2010.CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers.A novel transcript, VNN1-AB, as a biomarker for colorectal cancer.Prognostic markers for colorectal cancer; estimating ploidy and stroma.Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies.Chromatin organisation and cancer prognosis: a pan-cancer study.Sentinel node mapping does not improve staging of lymph node metastasis in colonic cancer.ColoGuidePro: a prognostic 7-gene expression signature for stage III colorectal cancer patients.Peritoneal carcinomatosis of colon cancer origin: highest incidence in women and in patients with right-sided tumors.CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer.The exon-level biomarker SLC39A14 has organ-confined cancer-specificity in colorectal cancer.Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer.CLC and IFNAR1 are differentially expressed and a global immunity score is distinct between early- and late-onset colorectal cancer
P50
Q33575005-4FE9EFA5-6327-4789-9289-7DACD721A200Q33608167-2984049C-AEC3-4270-B2D3-6F6B5CEE15B0Q33659798-C0D30593-C4E2-4804-847B-EE4470B2D87FQ33722799-BB83ED04-50B6-46A0-B7F0-AA5E0110654EQ33754380-7B3B6EB2-D55B-46EB-997B-F31C8EA00CF5Q34016649-1FF2314F-0413-466D-84FF-CA14321073AEQ34027064-732A6F1B-B0F1-401B-9815-14728C1418DCQ34105913-C516CD88-E406-44A7-B769-BA41331BAE26Q34423582-DD95568A-3662-4D5C-BBD8-0F530449D9CAQ34776216-857907D8-22BE-433A-8236-91B17030C1ACQ35114876-91B3FF28-215C-416B-BA76-8401F80D1A9AQ35194198-527D60E8-73B5-4927-9F6F-7530EEE50F12Q35216353-E6802752-063B-4B69-9425-9F2EF1285547Q36502335-51D6EBD2-7FD4-4DEF-BF51-6593B104D265Q36776983-BF3C3A1B-45BD-4C41-ABC0-4374C13AD84EQ37148928-9D4EF5EB-670B-4871-B8C7-2139D4AC5841Q37236012-25C116E7-43E1-4A54-A262-44605866ADC0Q37380747-6B942079-D7DE-4F33-B551-5A88C014BFBFQ37711656-31AD3A3A-F197-4001-900A-2FF21B16FA1DQ38275728-375A27FD-1B2F-46C1-996F-A9614BC5E11EQ38839775-CF02A06E-DCBF-4295-AC39-A8000C3F645CQ38882556-4292E660-1946-4BE5-B583-E9EB6701F479Q39324910-72D84767-0C0C-423F-A379-8FD3BC4A9731Q39484788-B40D1979-06FE-4B8D-BFFD-480510F6FFA6Q39665402-582770E1-FFD5-4CE7-A43A-E77885E5184AQ39704578-4D7C490F-1E82-4B89-A74F-664BD4043CFCQ39794257-000004A9-6FBC-4760-80EA-EC0ED5DFDCFFQ40997425-972B5C87-D355-4736-9251-7A39BED647BCQ41066289-4AFCEDFF-A402-48CB-9821-CD409F531115Q43700247-5A9FB146-6CE3-4114-91D1-7289576365DEQ47182054-73EE184E-5B80-4B3F-B83B-3BB78540A851Q49837351-E9E3B575-5C92-4655-A0B4-B80F858335EAQ50198699-D5E4A03E-2FC1-44AE-B543-2A8010C0B917Q50461077-4846F5F8-6DC0-4B95-B67E-55CE3F55AB89Q50784314-87332FE8-AC53-4E29-8038-7C6E5CA2C9D8Q51467202-D063D00E-8BA0-48FD-A451-DED381A83C80Q52666764-41A64208-2765-4573-A66E-08E7D9130645Q54333814-C5DCC476-DA17-4F0C-8530-8DA1259BF135Q55315504-9A4B5DE6-1710-4A02-84A6-AC700CCB710DQ58048546-8BFCEF0A-E35A-4118-AB01-988D4D63CDC2
P50
description
Noors onderzoeker
@nl
Norwegian researcher
@en
norsk forsker
@nb
name
Arild Nesbakken
@da
Arild Nesbakken
@de
Arild Nesbakken
@en
Arild Nesbakken
@es
Arild Nesbakken
@fr
Arild Nesbakken
@nb
Arild Nesbakken
@nl
Arild Nesbakken
@nn
Arild Nesbakken
@sl
Arild Nesbakken
@sq
type
label
Arild Nesbakken
@da
Arild Nesbakken
@de
Arild Nesbakken
@en
Arild Nesbakken
@es
Arild Nesbakken
@fr
Arild Nesbakken
@nb
Arild Nesbakken
@nl
Arild Nesbakken
@nn
Arild Nesbakken
@sl
Arild Nesbakken
@sq
prefLabel
Arild Nesbakken
@da
Arild Nesbakken
@de
Arild Nesbakken
@en
Arild Nesbakken
@es
Arild Nesbakken
@fr
Arild Nesbakken
@nb
Arild Nesbakken
@nl
Arild Nesbakken
@nn
Arild Nesbakken
@sl
Arild Nesbakken
@sq
P106
P2038
Arild_Nesbakken
P21
P214
4522149198296674940007
P2287
P27
P31
P569
1950-10-24T00:00:00Z
P735
P7859
viaf-4522149198296674940007